136446 20260219073610.0 GASTROENTEROLOGY & HEPATOLOGY 41 / 148 = 0.277 2024 Q2 T1 3.8 2024 Gastroenterology 2024 Q1 Hepatology 2024 Q2 1.091 2024 5.9 2024 ARTICLE (orcid)0000-0003-0076-3529 Gomollón, Fernando Universidad de Zaragoza (orcid)0000-0001-6883-8940 Casas, Diego Universidad de Zaragoza Iborra, Marisa Vela, Milagros Fernández-Clotet, Agnès Muñoz, Roser García de la Filia, Irene García Prada, María Ferrer Rosique, Juan Ángel García, María José de Francisco, Ruth Arias, Lara Barrio, Jesús Guerra, Iván Ponferrada, Ángel Gisbert, Javier P. Carrillo-Palau, Marta Calvet, Xavier Márquez-Mosquera, Lucía Gros, Beatriz Cañete, Fiorella Monfort, David Madrigal Domínguez, Rosa Eva Roncero, Óscar Laredo, Viviana (orcid)0000-0001-7676-9842 Montoro, Miguel Universidad de Zaragoza Muñoz, Carmen López-Cauce, Beatriz Lorente, Rufo Fuentes Coronel, Ana Vega, Pablo Martín, Dolores Peña, Elena Varela, Pilar Olivares, Sonsoles Pajares, Ramón Lucendo, Alfredo J. Sesé, Eva Botella Mateu, Belén Nos, Pilar Domènech, Eugeni (orcid)0000-0003-3970-5457 García-López, Santiago Universidad de Zaragoza ART-2024-139335 1719937 http://zaguan.unizar.es/record/136446/files/texto_completo.pdf Postprint info:eu-repo/date/embargoEnd/2025-06-15 2537380 http://zaguan.unizar.es/record/136446/files/texto_completo.jpg?subformat=icon icon Postprint info:eu-repo/date/embargoEnd/2025-06-15 2026-02-17-20:39:22 info:eu-repo/semantics/openAccess by-nc-nd https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Background some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible. Aims to assess the management of antiTNF-IP in IBD, and its impact in both diseases. Methods patients with antiTNF-IP from ENEIDA registry were included. Therapeutic strategy was classified as continuing the same antiTNF, stopping antiTNF, switch to another antiTNF or swap to a non-antiTNF biologic. IP severity and IBD activity were assessed at baseline and 16, 32 and 54 weeks. Results 234 patients were included. At baseline, antiTNF-IP was moderate-severe in 60 % of them, and IBD was in remission in 80 %. Therapeutic strategy was associated to antiTNF-IP severity (p < 0.001). AntiTNF-IP improved at week 54 with all strategies, but continuing with the same antiTNF showed the worst results (p = 0.042). Among patients with IBD in remission, relapse was higher in those who stopped antiTNF (p = 0.025). In multivariate analysis, stopping antiTNF, trunk and palms and soles location were associated with antiTNF-IP remission; female sex and previous surgery in Crohn´s disease with IBD relapse. Conclusion skin lesions severity and IBD activity seem to determine antiTNF-IP management. Continuing antiTNF in mild antiTNF-IP, and swap to ustekinumab or switch to another antiTNF in moderate-severe cases, are suitable strategies. Access copy available to the general public Unrestricted 56, 12 (2024), 2060-2068 Dig. liver dis. DIGESTIVE AND LIVER DISEASE 1590-8658 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study doi 10.1016/j.dld.2024.05.021 sideral 139335 2024 Sanz Segura, Patricia Universidad de Zaragoza eng oai:zaguan.unizar.es:136446 articulos driver